Is bigger always better? Not necessarily.

While PFS was not achieved in BioNTech’s cancer vaccine trial, there is still a chance for success with OS.

A vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center on April 16, 2021 in the Staten Island borough of New York City. Moderna is ...

MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

The company is looking to prove it can achieve significant success outside the coronavirus market.

Now, it’s worth noting Stock Advisor’s total average return is 937 % — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Washington: A federal judge in Delaware on Monday rejected Pfizer, BioNTech and Moderna's requests to dismiss patent lawsuits filed against them by Bayer's Monsanto unit over the messenger ...

Two names built on the same platform have stopped moving together this morning. Moderna (NASDAQ:MRNA) stock is up 11% to $154.15, a Tuesday morning session standing well apart from anything happening ...

BioNTech boasts a deep pipeline of candidates. One of the most promising products it is working on is called pumitamig. The biotech is developing it in collaboration with Bristol Myers Squibb(NYSE: ...